Skip to main content

Share story

Products

It's February 2, 2026 and the M&A Market is Booming

Pitchbook's Global M&A Report shows that merger and acquisition activity reached record levels in 2025. The report indicates that deal count and dollar value both set new highs and surpassed 2021 as the most active year in global M&A history. Momentum from the year is carrying into 2026. More than 50,000 transactions occurred in 2025. This represents a 12 percent increase from the prior year. The total value reached almost 5 trillion dollars, up 37 percent year over year. Average EBITDA multiples climbed to 10.1 times in 2025 from 8.8 times in 2022. Enterprise value to revenue multiples rose to 1.7 times from 1.5 times in 2023. The fourth quarter of 2025 marked the strongest quarter in M&A history. There were 617 deals exceeding 1 billion dollars in 2025. This figure is up 62 percent from the previous year. Such mega deals made up 1.5 percent of the total number but accounted for 57 percent of the overall dollar value. Factors supporting the environment include higher equity values, modestly lower borrowing costs, increased investor confidence and a favorable regulatory environment.
Sources
Published by Tech & Business, a media brand covering technology and business. This story was sourced from Woodside Capital Partners and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.